nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—Obstructive airways disorder—Methotrexate—esophageal cancer	0.0193	0.0438	CcSEcCtD
Darifenacin—Depressed mood—Capecitabine—esophageal cancer	0.0131	0.0299	CcSEcCtD
Darifenacin—Infection—Carboplatin—esophageal cancer	0.00963	0.0219	CcSEcCtD
Darifenacin—Ulcerative stomatitis—Methotrexate—esophageal cancer	0.00948	0.0216	CcSEcCtD
Darifenacin—Pain—Carboplatin—esophageal cancer	0.00829	0.0189	CcSEcCtD
Darifenacin—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00591	0.0134	CcSEcCtD
Darifenacin—Clotrimazole—ABCC2—esophageal cancer	0.00589	0.194	CrCbGaD
Darifenacin—Clotrimazole—CYP2A6—esophageal cancer	0.00582	0.192	CrCbGaD
Darifenacin—Face oedema—Cisplatin—esophageal cancer	0.00559	0.0127	CcSEcCtD
Darifenacin—Clotrimazole—CYP19A1—esophageal cancer	0.00554	0.182	CrCbGaD
Darifenacin—Dry eye—Capecitabine—esophageal cancer	0.00543	0.0123	CcSEcCtD
Darifenacin—Mouth ulceration—Capecitabine—esophageal cancer	0.00531	0.0121	CcSEcCtD
Darifenacin—Breast disorder—Cisplatin—esophageal cancer	0.00523	0.0119	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00521	0.0119	CcSEcCtD
Darifenacin—Abnormal vision—Capecitabine—esophageal cancer	0.00513	0.0117	CcSEcCtD
Darifenacin—Mental disability—Capecitabine—esophageal cancer	0.0051	0.0116	CcSEcCtD
Darifenacin—Vaginal inflammation—Methotrexate—esophageal cancer	0.00437	0.00995	CcSEcCtD
Darifenacin—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00435	0.0099	CcSEcCtD
Darifenacin—Stomatitis—Cisplatin—esophageal cancer	0.00435	0.00989	CcSEcCtD
Darifenacin—Vaginal infection—Methotrexate—esophageal cancer	0.00413	0.00939	CcSEcCtD
Darifenacin—Face oedema—Capecitabine—esophageal cancer	0.00412	0.00937	CcSEcCtD
Darifenacin—Urinary retention—Capecitabine—esophageal cancer	0.00406	0.00923	CcSEcCtD
Darifenacin—Bladder pain—Methotrexate—esophageal cancer	0.00396	0.009	CcSEcCtD
Darifenacin—Mouth ulceration—Methotrexate—esophageal cancer	0.00396	0.009	CcSEcCtD
Darifenacin—Urinary tract disorder—Cisplatin—esophageal cancer	0.00395	0.00899	CcSEcCtD
Darifenacin—Urethral disorder—Cisplatin—esophageal cancer	0.00392	0.00893	CcSEcCtD
Darifenacin—Dry skin—Capecitabine—esophageal cancer	0.00391	0.00889	CcSEcCtD
Darifenacin—Visual impairment—Cisplatin—esophageal cancer	0.00386	0.00878	CcSEcCtD
Darifenacin—Breast disorder—Capecitabine—esophageal cancer	0.00385	0.00877	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00384	0.00874	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00376	0.00856	CcSEcCtD
Darifenacin—Eye disorder—Cisplatin—esophageal cancer	0.00374	0.00851	CcSEcCtD
Darifenacin—Influenza—Capecitabine—esophageal cancer	0.00369	0.00839	CcSEcCtD
Darifenacin—Mediastinal disorder—Cisplatin—esophageal cancer	0.00361	0.00821	CcSEcCtD
Darifenacin—Bronchitis—Capecitabine—esophageal cancer	0.00355	0.00807	CcSEcCtD
Darifenacin—Flatulence—Cisplatin—esophageal cancer	0.00343	0.00781	CcSEcCtD
Darifenacin—Weight increased—Capecitabine—esophageal cancer	0.00336	0.00763	CcSEcCtD
Darifenacin—Visual disturbance—Methotrexate—esophageal cancer	0.00335	0.00762	CcSEcCtD
Darifenacin—Infestation NOS—Capecitabine—esophageal cancer	0.00329	0.00748	CcSEcCtD
Darifenacin—Infestation—Capecitabine—esophageal cancer	0.00329	0.00748	CcSEcCtD
Darifenacin—Vision blurred—Cisplatin—esophageal cancer	0.00328	0.00747	CcSEcCtD
Darifenacin—Methadone—CYP19A1—esophageal cancer	0.00325	0.107	CrCbGaD
Darifenacin—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00324	0.00737	CcSEcCtD
Darifenacin—Stomatitis—Capecitabine—esophageal cancer	0.0032	0.00729	CcSEcCtD
Darifenacin—Urinary tract infection—Capecitabine—esophageal cancer	0.0032	0.00727	CcSEcCtD
Darifenacin—Rhinitis—Capecitabine—esophageal cancer	0.00296	0.00673	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00295	0.0067	CcSEcCtD
Darifenacin—Pharyngitis—Capecitabine—esophageal cancer	0.00293	0.00666	CcSEcCtD
Darifenacin—Urinary tract disorder—Capecitabine—esophageal cancer	0.00291	0.00663	CcSEcCtD
Darifenacin—Oedema peripheral—Capecitabine—esophageal cancer	0.00291	0.00661	CcSEcCtD
Darifenacin—Urethral disorder—Capecitabine—esophageal cancer	0.00289	0.00658	CcSEcCtD
Darifenacin—Breast disorder—Methotrexate—esophageal cancer	0.00287	0.00653	CcSEcCtD
Darifenacin—Anaphylactic shock—Cisplatin—esophageal cancer	0.00284	0.00647	CcSEcCtD
Darifenacin—Oedema—Cisplatin—esophageal cancer	0.00284	0.00647	CcSEcCtD
Darifenacin—Visual impairment—Capecitabine—esophageal cancer	0.00284	0.00647	CcSEcCtD
Darifenacin—Infection—Cisplatin—esophageal cancer	0.00283	0.00643	CcSEcCtD
Darifenacin—Fexofenadine—ABCB1—esophageal cancer	0.0028	0.0923	CrCbGaD
Darifenacin—Erythema multiforme—Capecitabine—esophageal cancer	0.00279	0.00635	CcSEcCtD
Darifenacin—Nervous system disorder—Cisplatin—esophageal cancer	0.00279	0.00634	CcSEcCtD
Darifenacin—Tachycardia—Cisplatin—esophageal cancer	0.00278	0.00631	CcSEcCtD
Darifenacin—Skin disorder—Cisplatin—esophageal cancer	0.00276	0.00628	CcSEcCtD
Darifenacin—Eye disorder—Capecitabine—esophageal cancer	0.00276	0.00627	CcSEcCtD
Darifenacin—Hyperhidrosis—Cisplatin—esophageal cancer	0.00275	0.00625	CcSEcCtD
Darifenacin—Angiopathy—Capecitabine—esophageal cancer	0.00268	0.00609	CcSEcCtD
Darifenacin—Mediastinal disorder—Capecitabine—esophageal cancer	0.00266	0.00605	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00259	0.00589	CcSEcCtD
Darifenacin—Mental disorder—Capecitabine—esophageal cancer	0.00259	0.00588	CcSEcCtD
Darifenacin—Dyspnoea—Cisplatin—esophageal cancer	0.00254	0.00577	CcSEcCtD
Darifenacin—Flatulence—Capecitabine—esophageal cancer	0.00253	0.00576	CcSEcCtD
Darifenacin—Erectile dysfunction—Methotrexate—esophageal cancer	0.00253	0.00575	CcSEcCtD
Darifenacin—Dysgeusia—Capecitabine—esophageal cancer	0.00252	0.00572	CcSEcCtD
Darifenacin—Back pain—Capecitabine—esophageal cancer	0.00248	0.00565	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00246	0.00559	CcSEcCtD
Darifenacin—Infestation NOS—Methotrexate—esophageal cancer	0.00245	0.00557	CcSEcCtD
Darifenacin—Infestation—Methotrexate—esophageal cancer	0.00245	0.00557	CcSEcCtD
Darifenacin—Pain—Cisplatin—esophageal cancer	0.00243	0.00553	CcSEcCtD
Darifenacin—Vision blurred—Capecitabine—esophageal cancer	0.00242	0.00551	CcSEcCtD
Darifenacin—Stomatitis—Methotrexate—esophageal cancer	0.00239	0.00543	CcSEcCtD
Darifenacin—Sweating—Methotrexate—esophageal cancer	0.00235	0.00534	CcSEcCtD
Darifenacin—Feeling abnormal—Cisplatin—esophageal cancer	0.00234	0.00533	CcSEcCtD
Darifenacin—Syncope—Capecitabine—esophageal cancer	0.0023	0.00524	CcSEcCtD
Darifenacin—Palpitations—Capecitabine—esophageal cancer	0.00227	0.00516	CcSEcCtD
Darifenacin—Loss of consciousness—Capecitabine—esophageal cancer	0.00226	0.00514	CcSEcCtD
Darifenacin—Cough—Capecitabine—esophageal cancer	0.00224	0.0051	CcSEcCtD
Darifenacin—Hypertension—Capecitabine—esophageal cancer	0.00222	0.00505	CcSEcCtD
Darifenacin—Arthralgia—Capecitabine—esophageal cancer	0.00219	0.00497	CcSEcCtD
Darifenacin—Pharyngitis—Methotrexate—esophageal cancer	0.00218	0.00496	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00217	0.00494	CcSEcCtD
Darifenacin—Urinary tract disorder—Methotrexate—esophageal cancer	0.00217	0.00494	CcSEcCtD
Darifenacin—Clotrimazole—ABCB1—esophageal cancer	0.00217	0.0713	CrCbGaD
Darifenacin—Urethral disorder—Methotrexate—esophageal cancer	0.00215	0.0049	CcSEcCtD
Darifenacin—Dry mouth—Capecitabine—esophageal cancer	0.00214	0.00487	CcSEcCtD
Darifenacin—Visual impairment—Methotrexate—esophageal cancer	0.00212	0.00482	CcSEcCtD
Darifenacin—Confusional state—Capecitabine—esophageal cancer	0.00211	0.00481	CcSEcCtD
Darifenacin—Oedema—Capecitabine—esophageal cancer	0.0021	0.00477	CcSEcCtD
Darifenacin—Hypersensitivity—Cisplatin—esophageal cancer	0.0021	0.00477	CcSEcCtD
Darifenacin—Infection—Capecitabine—esophageal cancer	0.00208	0.00474	CcSEcCtD
Darifenacin—Erythema multiforme—Methotrexate—esophageal cancer	0.00208	0.00472	CcSEcCtD
Darifenacin—Shock—Capecitabine—esophageal cancer	0.00206	0.00469	CcSEcCtD
Darifenacin—Nervous system disorder—Capecitabine—esophageal cancer	0.00206	0.00468	CcSEcCtD
Darifenacin—Eye disorder—Methotrexate—esophageal cancer	0.00205	0.00467	CcSEcCtD
Darifenacin—Tachycardia—Capecitabine—esophageal cancer	0.00205	0.00465	CcSEcCtD
Darifenacin—Asthenia—Cisplatin—esophageal cancer	0.00204	0.00464	CcSEcCtD
Darifenacin—Skin disorder—Capecitabine—esophageal cancer	0.00204	0.00463	CcSEcCtD
Darifenacin—Hyperhidrosis—Capecitabine—esophageal cancer	0.00203	0.00461	CcSEcCtD
Darifenacin—Angiopathy—Methotrexate—esophageal cancer	0.00199	0.00453	CcSEcCtD
Darifenacin—Mediastinal disorder—Methotrexate—esophageal cancer	0.00198	0.0045	CcSEcCtD
Darifenacin—Diarrhoea—Cisplatin—esophageal cancer	0.00195	0.00443	CcSEcCtD
Darifenacin—Mental disorder—Methotrexate—esophageal cancer	0.00192	0.00438	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00191	0.00435	CcSEcCtD
Darifenacin—Insomnia—Capecitabine—esophageal cancer	0.0019	0.00431	CcSEcCtD
Darifenacin—Dysgeusia—Methotrexate—esophageal cancer	0.00187	0.00426	CcSEcCtD
Darifenacin—Dyspnoea—Capecitabine—esophageal cancer	0.00187	0.00425	CcSEcCtD
Darifenacin—Fentanyl—ABCB1—esophageal cancer	0.00185	0.061	CrCbGaD
Darifenacin—Back pain—Methotrexate—esophageal cancer	0.00185	0.00421	CcSEcCtD
Darifenacin—Dyspepsia—Capecitabine—esophageal cancer	0.00185	0.0042	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00181	0.00412	CcSEcCtD
Darifenacin—Vomiting—Cisplatin—esophageal cancer	0.00181	0.00411	CcSEcCtD
Darifenacin—Vision blurred—Methotrexate—esophageal cancer	0.0018	0.0041	CcSEcCtD
Darifenacin—Rash—Cisplatin—esophageal cancer	0.00179	0.00408	CcSEcCtD
Darifenacin—Pain—Capecitabine—esophageal cancer	0.00179	0.00408	CcSEcCtD
Darifenacin—Constipation—Capecitabine—esophageal cancer	0.00179	0.00408	CcSEcCtD
Darifenacin—Dermatitis—Cisplatin—esophageal cancer	0.00179	0.00408	CcSEcCtD
Darifenacin—Loperamide—ABCB1—esophageal cancer	0.00178	0.0587	CrCbGaD
Darifenacin—Feeling abnormal—Capecitabine—esophageal cancer	0.00173	0.00393	CcSEcCtD
Darifenacin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00171	0.0039	CcSEcCtD
Darifenacin—Nausea—Cisplatin—esophageal cancer	0.00169	0.00384	CcSEcCtD
Darifenacin—Cough—Methotrexate—esophageal cancer	0.00167	0.0038	CcSEcCtD
Darifenacin—Abdominal pain—Capecitabine—esophageal cancer	0.00166	0.00377	CcSEcCtD
Darifenacin—Arthralgia—Methotrexate—esophageal cancer	0.00163	0.0037	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00162	0.00368	CcSEcCtD
Darifenacin—Confusional state—Methotrexate—esophageal cancer	0.00157	0.00358	CcSEcCtD
Darifenacin—Anaphylactic shock—Methotrexate—esophageal cancer	0.00156	0.00355	CcSEcCtD
Darifenacin—Infection—Methotrexate—esophageal cancer	0.00155	0.00353	CcSEcCtD
Darifenacin—Hypersensitivity—Capecitabine—esophageal cancer	0.00154	0.00351	CcSEcCtD
Darifenacin—Nervous system disorder—Methotrexate—esophageal cancer	0.00153	0.00348	CcSEcCtD
Darifenacin—Skin disorder—Methotrexate—esophageal cancer	0.00152	0.00345	CcSEcCtD
Darifenacin—Hyperhidrosis—Methotrexate—esophageal cancer	0.00151	0.00343	CcSEcCtD
Darifenacin—Asthenia—Capecitabine—esophageal cancer	0.0015	0.00342	CcSEcCtD
Darifenacin—Pruritus—Capecitabine—esophageal cancer	0.00148	0.00337	CcSEcCtD
Darifenacin—Diarrhoea—Capecitabine—esophageal cancer	0.00143	0.00326	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00142	0.00323	CcSEcCtD
Darifenacin—Insomnia—Methotrexate—esophageal cancer	0.00141	0.00321	CcSEcCtD
Darifenacin—Dyspnoea—Methotrexate—esophageal cancer	0.00139	0.00317	CcSEcCtD
Darifenacin—Somnolence—Methotrexate—esophageal cancer	0.00139	0.00316	CcSEcCtD
Darifenacin—Dizziness—Capecitabine—esophageal cancer	0.00139	0.00315	CcSEcCtD
Darifenacin—Dyspepsia—Methotrexate—esophageal cancer	0.00137	0.00313	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00135	0.00307	CcSEcCtD
Darifenacin—Pain—Methotrexate—esophageal cancer	0.00133	0.00304	CcSEcCtD
Darifenacin—Vomiting—Capecitabine—esophageal cancer	0.00133	0.00303	CcSEcCtD
Darifenacin—Rash—Capecitabine—esophageal cancer	0.00132	0.00301	CcSEcCtD
Darifenacin—Dermatitis—Capecitabine—esophageal cancer	0.00132	0.003	CcSEcCtD
Darifenacin—Headache—Capecitabine—esophageal cancer	0.00131	0.00299	CcSEcCtD
Darifenacin—Feeling abnormal—Methotrexate—esophageal cancer	0.00129	0.00293	CcSEcCtD
Darifenacin—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00128	0.0029	CcSEcCtD
Darifenacin—Methadone—ABCB1—esophageal cancer	0.00127	0.0418	CrCbGaD
Darifenacin—Nausea—Capecitabine—esophageal cancer	0.00125	0.00283	CcSEcCtD
Darifenacin—Abdominal pain—Methotrexate—esophageal cancer	0.00123	0.00281	CcSEcCtD
Darifenacin—Hypersensitivity—Methotrexate—esophageal cancer	0.00115	0.00262	CcSEcCtD
Darifenacin—Asthenia—Methotrexate—esophageal cancer	0.00112	0.00255	CcSEcCtD
Darifenacin—Pruritus—Methotrexate—esophageal cancer	0.0011	0.00251	CcSEcCtD
Darifenacin—Diarrhoea—Methotrexate—esophageal cancer	0.00107	0.00243	CcSEcCtD
Darifenacin—Dizziness—Methotrexate—esophageal cancer	0.00103	0.00235	CcSEcCtD
Darifenacin—Vomiting—Methotrexate—esophageal cancer	0.000992	0.00226	CcSEcCtD
Darifenacin—Rash—Methotrexate—esophageal cancer	0.000984	0.00224	CcSEcCtD
Darifenacin—Dermatitis—Methotrexate—esophageal cancer	0.000983	0.00224	CcSEcCtD
Darifenacin—Headache—Methotrexate—esophageal cancer	0.000978	0.00222	CcSEcCtD
Darifenacin—Nausea—Methotrexate—esophageal cancer	0.000927	0.00211	CcSEcCtD
Darifenacin—CHRM3—Signaling by GPCR—GHRL—esophageal cancer	0.000271	0.000511	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PFN1—esophageal cancer	0.000271	0.000511	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CXCL2—esophageal cancer	0.00027	0.00051	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PFN1—esophageal cancer	0.00027	0.000509	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—GHRL—esophageal cancer	0.000268	0.000506	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PFN1—esophageal cancer	0.000267	0.000504	CbGpPWpGaD
Darifenacin—CHRM1—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000266	0.000502	CbGpPWpGaD
Darifenacin—CHRM3—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000265	0.000501	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CA1—esophageal cancer	0.000263	0.000496	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000263	0.000496	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GAPDH—esophageal cancer	0.000261	0.000493	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CTNNA1—esophageal cancer	0.00026	0.000491	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CRABP1—esophageal cancer	0.000259	0.000489	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CXCL2—esophageal cancer	0.000259	0.000488	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PSME1—esophageal cancer	0.000252	0.000476	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PSME2—esophageal cancer	0.000252	0.000476	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—ANXA1—esophageal cancer	0.000251	0.000474	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GNG7—esophageal cancer	0.000246	0.000465	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SST—esophageal cancer	0.000244	0.000461	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ELMO1—esophageal cancer	0.000243	0.000459	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—TP53—esophageal cancer	0.000243	0.000459	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ELMO1—esophageal cancer	0.000242	0.000457	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PSME2—esophageal cancer	0.000242	0.000456	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PSME1—esophageal cancer	0.000242	0.000456	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—ANXA1—esophageal cancer	0.00024	0.000454	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CA2—esophageal cancer	0.00024	0.000454	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ELMO1—esophageal cancer	0.00024	0.000453	CbGpPWpGaD
Darifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000238	0.000449	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NOTCH3—esophageal cancer	0.000238	0.000449	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—GHRL—esophageal cancer	0.000238	0.000449	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AKAP13—esophageal cancer	0.000238	0.000448	CbGpPWpGaD
Darifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000237	0.000448	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AKAP13—esophageal cancer	0.000237	0.000447	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AKAP13—esophageal cancer	0.000235	0.000443	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—FBXW7—esophageal cancer	0.000234	0.000442	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SST—esophageal cancer	0.000234	0.000441	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ALDH2—esophageal cancer	0.000231	0.000436	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—GHRL—esophageal cancer	0.000228	0.00043	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NOTCH3—esophageal cancer	0.000228	0.00043	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—FBXW7—esophageal cancer	0.000224	0.000423	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000224	0.000422	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000224	0.000422	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GSTT1—esophageal cancer	0.00022	0.000414	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000219	0.000414	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000219	0.000412	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PDE4D—esophageal cancer	0.000217	0.00041	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CYP2A6—esophageal cancer	0.000217	0.00041	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PDE4D—esophageal cancer	0.000217	0.000409	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000216	0.000408	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PDE4D—esophageal cancer	0.000215	0.000405	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NOTCH2—esophageal cancer	0.000214	0.000403	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—GNG7—esophageal cancer	0.000207	0.00039	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—GNG7—esophageal cancer	0.000206	0.000389	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ENO1—esophageal cancer	0.000206	0.000388	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTGS1—esophageal cancer	0.000206	0.000388	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NOTCH2—esophageal cancer	0.000204	0.000386	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—GNG7—esophageal cancer	0.000204	0.000385	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PSME1—esophageal cancer	0.000203	0.000383	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PSME2—esophageal cancer	0.000203	0.000383	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000202	0.000381	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000202	0.000381	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000196	0.00037	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—XIAP—esophageal cancer	0.000194	0.000365	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—XIAP—esophageal cancer	0.000193	0.000364	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—XIAP—esophageal cancer	0.000191	0.000361	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TGFBR2—esophageal cancer	0.000189	0.000357	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000187	0.000353	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CTNNA1—esophageal cancer	0.000183	0.000346	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CTNNA1—esophageal cancer	0.000183	0.000345	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000182	0.000344	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CXCL2—esophageal cancer	0.000182	0.000344	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CXCL2—esophageal cancer	0.000182	0.000343	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TGFBR2—esophageal cancer	0.000181	0.000342	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CTNNA1—esophageal cancer	0.000181	0.000341	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CXCL2—esophageal cancer	0.00018	0.000339	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SMAD4—esophageal cancer	0.000179	0.000338	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000178	0.000335	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CYP1B1—esophageal cancer	0.000175	0.00033	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CA1—esophageal cancer	0.000172	0.000324	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000172	0.000324	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SMAD4—esophageal cancer	0.000172	0.000324	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PSME1—esophageal cancer	0.00017	0.000321	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PSME2—esophageal cancer	0.00017	0.000321	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PSME1—esophageal cancer	0.00017	0.00032	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PSME2—esophageal cancer	0.00017	0.00032	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000169	0.00032	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000169	0.00032	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ANXA1—esophageal cancer	0.000169	0.000319	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ANXA1—esophageal cancer	0.000169	0.000318	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PSME1—esophageal cancer	0.000168	0.000317	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PSME2—esophageal cancer	0.000168	0.000317	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ANXA1—esophageal cancer	0.000167	0.000315	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SST—esophageal cancer	0.000165	0.000311	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CYP19A1—esophageal cancer	0.000165	0.00031	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SST—esophageal cancer	0.000164	0.00031	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SST—esophageal cancer	0.000163	0.000307	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000162	0.000306	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NOTCH3—esophageal cancer	0.000161	0.000303	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—GHRL—esophageal cancer	0.000161	0.000303	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NOTCH3—esophageal cancer	0.00016	0.000302	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—GHRL—esophageal cancer	0.00016	0.000302	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NOTCH3—esophageal cancer	0.000158	0.000299	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—GHRL—esophageal cancer	0.000158	0.000299	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—FBXW7—esophageal cancer	0.000158	0.000298	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—FBXW7—esophageal cancer	0.000157	0.000297	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CA2—esophageal cancer	0.000157	0.000297	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000156	0.000295	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—FBXW7—esophageal cancer	0.000156	0.000294	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000155	0.000292	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—HMOX1—esophageal cancer	0.00015	0.000283	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GNG7—esophageal cancer	0.000147	0.000278	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—HIF1A—esophageal cancer	0.000147	0.000277	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.000146	0.000276	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ADH7—esophageal cancer	0.000146	0.000276	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ABCB1—esophageal cancer	0.000144	0.000272	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NOTCH2—esophageal cancer	0.000144	0.000272	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NOTCH2—esophageal cancer	0.000144	0.000271	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NOTCH2—esophageal cancer	0.000142	0.000268	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—HIF1A—esophageal cancer	0.00014	0.000265	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—KDR—esophageal cancer	0.00014	0.000265	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALDH2—esophageal cancer	0.000138	0.000261	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—KDR—esophageal cancer	0.000134	0.000254	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NOTCH1—esophageal cancer	0.000132	0.000249	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTT1—esophageal cancer	0.000131	0.000248	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP2A6—esophageal cancer	0.00013	0.000245	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ADH1B—esophageal cancer	0.000128	0.000242	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TGFBR2—esophageal cancer	0.000128	0.000241	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TGFBR2—esophageal cancer	0.000127	0.00024	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NOTCH1—esophageal cancer	0.000127	0.000239	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TGFBR2—esophageal cancer	0.000126	0.000238	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ENO1—esophageal cancer	0.000123	0.000232	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTGS1—esophageal cancer	0.000123	0.000232	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—TYMP—esophageal cancer	0.000122	0.000231	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PSME2—esophageal cancer	0.000121	0.000229	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PSME1—esophageal cancer	0.000121	0.000229	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SMAD4—esophageal cancer	0.000121	0.000228	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SMAD4—esophageal cancer	0.000121	0.000227	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CREBBP—esophageal cancer	0.00012	0.000226	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SMAD4—esophageal cancer	0.000119	0.000225	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP26A1—esophageal cancer	0.000119	0.000225	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—EGFR—esophageal cancer	0.000118	0.000222	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALOX15—esophageal cancer	0.000116	0.000219	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CREBBP—esophageal cancer	0.000115	0.000217	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—EGFR—esophageal cancer	0.000113	0.000213	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000113	0.000212	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTO1—esophageal cancer	0.000111	0.000209	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—TPI1—esophageal cancer	0.000111	0.000209	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000108	0.000203	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NOS3—esophageal cancer	0.000107	0.000202	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALDOB—esophageal cancer	0.000106	0.0002	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP1B1—esophageal cancer	0.000105	0.000197	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NOS3—esophageal cancer	0.000103	0.000194	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GAPDH—esophageal cancer	0.000102	0.000193	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—PIK3CA—esophageal cancer	0.000102	0.000193	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CRABP1—esophageal cancer	0.000101	0.000191	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—ERBB2—esophageal cancer	0.0001	0.000189	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HIF1A—esophageal cancer	9.89e-05	0.000187	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HIF1A—esophageal cancer	9.86e-05	0.000186	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP19A1—esophageal cancer	9.84e-05	0.000186	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—PIK3CA—esophageal cancer	9.79e-05	0.000185	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HIF1A—esophageal cancer	9.76e-05	0.000184	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GNG7—esophageal cancer	9.63e-05	0.000182	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CREBBP—esophageal cancer	9.63e-05	0.000182	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—ERBB2—esophageal cancer	9.61e-05	0.000181	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KDR—esophageal cancer	9.46e-05	0.000178	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KDR—esophageal cancer	9.43e-05	0.000178	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KDR—esophageal cancer	9.34e-05	0.000176	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALDH2—esophageal cancer	9.03e-05	0.00017	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—HMOX1—esophageal cancer	8.98e-05	0.000169	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NOTCH1—esophageal cancer	8.91e-05	0.000168	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NOTCH1—esophageal cancer	8.88e-05	0.000168	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCND1—esophageal cancer	8.87e-05	0.000167	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NOTCH1—esophageal cancer	8.8e-05	0.000166	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—NOS3—esophageal cancer	8.62e-05	0.000163	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ABCB1—esophageal cancer	8.62e-05	0.000163	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTT1—esophageal cancer	8.59e-05	0.000162	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CDKN1A—esophageal cancer	8.58e-05	0.000162	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCND1—esophageal cancer	8.49e-05	0.00016	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP2A6—esophageal cancer	8.49e-05	0.00016	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CDKN1A—esophageal cancer	8.21e-05	0.000155	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EP300—esophageal cancer	8.16e-05	0.000154	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	8.08e-05	0.000152	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CREBBP—esophageal cancer	8.05e-05	0.000152	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ENO1—esophageal cancer	8.05e-05	0.000152	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTGS1—esophageal cancer	8.05e-05	0.000152	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CREBBP—esophageal cancer	7.98e-05	0.00015	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	7.94e-05	0.00015	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PSME1—esophageal cancer	7.93e-05	0.00015	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PSME2—esophageal cancer	7.93e-05	0.00015	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—EGFR—esophageal cancer	7.91e-05	0.000149	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTGS2—esophageal cancer	7.89e-05	0.000149	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—EGFR—esophageal cancer	7.84e-05	0.000148	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EP300—esophageal cancer	7.82e-05	0.000147	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	7.59e-05	0.000143	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—PIK3CA—esophageal cancer	7.56e-05	0.000143	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—PIK3CA—esophageal cancer	7.49e-05	0.000141	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NOS3—esophageal cancer	7.23e-05	0.000136	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NOS3—esophageal cancer	7.21e-05	0.000136	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NOS3—esophageal cancer	7.14e-05	0.000135	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MYC—esophageal cancer	7.11e-05	0.000134	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EGFR—esophageal cancer	6.96e-05	0.000131	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	6.89e-05	0.00013	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—PIK3CA—esophageal cancer	6.87e-05	0.00013	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP1B1—esophageal cancer	6.84e-05	0.000129	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MYC—esophageal cancer	6.81e-05	0.000128	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—PIK3CA—esophageal cancer	6.8e-05	0.000128	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	6.77e-05	0.000128	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ERBB2—esophageal cancer	6.75e-05	0.000127	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ERBB2—esophageal cancer	6.68e-05	0.000126	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EGFR—esophageal cancer	6.66e-05	0.000126	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—EP300—esophageal cancer	6.56e-05	0.000124	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP19A1—esophageal cancer	6.43e-05	0.000121	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PIK3CA—esophageal cancer	6.04e-05	0.000114	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCND1—esophageal cancer	5.98e-05	0.000113	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCND1—esophageal cancer	5.96e-05	0.000112	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCND1—esophageal cancer	5.9e-05	0.000111	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HMOX1—esophageal cancer	5.87e-05	0.000111	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TP53—esophageal cancer	5.84e-05	0.00011	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	5.78e-05	0.000109	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PIK3CA—esophageal cancer	5.78e-05	0.000109	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CDKN1A—esophageal cancer	5.76e-05	0.000109	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CREBBP—esophageal cancer	5.76e-05	0.000109	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CDKN1A—esophageal cancer	5.71e-05	0.000108	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ABCB1—esophageal cancer	5.63e-05	0.000106	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TP53—esophageal cancer	5.59e-05	0.000106	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EP300—esophageal cancer	5.5e-05	0.000104	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EP300—esophageal cancer	5.49e-05	0.000103	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EP300—esophageal cancer	5.43e-05	0.000102	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—NOS3—esophageal cancer	5.16e-05	9.73e-05	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PIK3CA—esophageal cancer	4.85e-05	9.16e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MYC—esophageal cancer	4.8e-05	9.05e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MYC—esophageal cancer	4.78e-05	9.02e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MYC—esophageal cancer	4.73e-05	8.93e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTGS2—esophageal cancer	4.72e-05	8.9e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGFR—esophageal cancer	4.69e-05	8.85e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGFR—esophageal cancer	4.68e-05	8.82e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGFR—esophageal cancer	4.63e-05	8.74e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	4.07e-05	7.68e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PIK3CA—esophageal cancer	4.06e-05	7.66e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PIK3CA—esophageal cancer	4.02e-05	7.58e-05	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TP53—esophageal cancer	3.94e-05	7.43e-05	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TP53—esophageal cancer	3.93e-05	7.41e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—EP300—esophageal cancer	3.92e-05	7.4e-05	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TP53—esophageal cancer	3.89e-05	7.33e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.77e-05	7.1e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NOS3—esophageal cancer	3.37e-05	6.36e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.08e-05	5.82e-05	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2.9e-05	5.47e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—EP300—esophageal cancer	2.56e-05	4.84e-05	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.9e-05	3.58e-05	CbGpPWpGaD
